Platform pure-plays

Who owns the visible layer

Quantum's platform pure-plays are a chokepoint of a strange kind: the asset isn't a fab or a mine, it's the only liquid claims on the fault-tolerance race. Public-market capital that wants direct quantum-hardware exposure has a handful of doors — IonQ, Quantinuum, Rigetti, D-Wave — and every benchmark, government down-select, and logical-qubit record reprices them violently. The cohort just got its anchor tenant: Quantinuum's June 2026 IPO (NASDAQ: QNT) raised $1.68B at a ~$15.7B market cap on first-day close (the IPO priced nearer $14B; intraday peak touched ~$17.6B), the first traditional listing of a full-stack quantum computer maker.

The moat splits the cohort in two. IonQ and Quantinuum own capital plus external validation: IonQ ended Q1 2026 with $3.1B in cash and investments, $64.7M of quarterly revenue and a record $470M of RPO, and both were among the 11 teams DARPA advanced to Stage B of its Quantum Benchmarking Initiative — the government's structured attempt to verify or falsify utility-scale roadmaps by 2033. Quantinuum's Helios runs 48 error-corrected logical qubits on 98 physical ones, the best conversion ratio publicly disclosed, with fully fault-tolerant Apollo targeted for around 2029 — the company's own language is "by the end of the decade." Behind them, Rigetti ($569M cash, no debt, 108-qubit Cepheus now generally available) and D-Wave ($588M cash, record $33.4M Q1 bookings) are funded but fighting for credibility — Rigetti missed the initial QBI Stage B cut.

Be clear-eyed about scale: cohort trailing revenue sits in the low hundreds of millions against combined market value in the tens of billions, and even Quantinuum booked just $30.9M of 2025 revenue. The chokepoint is scarcity of access, not size of market.

What breaks it

Three things. First, a conglomerate wins: IBM sits inside the same DARPA Stage B cohort with a superconducting roadmap funded by petty cash — if fault tolerance arrives as a hyperscaler feature, the pure-play scarcity premium evaporates. Second, private capital leapfrogs: PsiQuantum raised $1B at a $7B valuation from BlackRock-managed funds and Nvidia's NVentures to skip straight to utility-scale photonics in Chicago and Brisbane, and its eventual IPO — or QuEra's — dilutes the scarcity propping up today's multiples. Third, the dilution treadmill stalls: IonQ's adjusted EBITDA loss was $96.8M in Q1 alone, and every name here funds itself off equity windows. The moat is mark-to-market confidence; it compounds while windows are open and dies when they close.

The repricing event

DARPA's Stage B verdicts, expected around late 2026, are the next forced grading: advancing to Stage C is a credibility moat money can't buy, and exclusion puts a government stamp on roadmap doubt — see Rigetti's tape after the November 2025 announcement. Before that, August prints (IonQ around Aug 12) test whether acquisition-built backlog converts to organic revenue, Quantinuum reports its first quarters as a public company, and Congress moves the National Quantum Initiative Reauthorization Act, which would extend and expand federal quantum funding through 2034.